Stephen Hanauer to Drug Administration Schedule
This is a "connection" page, showing publications Stephen Hanauer has written about Drug Administration Schedule.
Connection Strength
0.979
-
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. J Crohns Colitis. 2020 Jan 01; 14(1):23-32.
Score: 0.158
-
Clinical perspectives in Crohn's disease. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down". Rev Gastroenterol Disord. 2007; 7 Suppl 2:S17-22.
Score: 0.064
-
Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther. 2006 Oct; 24 Suppl 3:37-40.
Score: 0.063
-
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006 Mar; 63(3):433-42; quiz 464.
Score: 0.061
-
Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease. Am J Gastroenterol. 2005 Jul; 100(7):1438-9.
Score: 0.058
-
Treatment of Crohn's disease: the "long" of it. Gastroenterology. 2005 Jun; 128(7):2164-6.
Score: 0.057
-
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther. 2005 Feb 15; 21(4):373-84.
Score: 0.056
-
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004 Jul; 2(7):542-53.
Score: 0.054
-
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004 Feb; 126(2):402-13.
Score: 0.052
-
Immunogenicity of infliximab in Crohn's disease. N Engl J Med. 2003 May 22; 348(21):2155-6; author reply 2155-6.
Score: 0.050
-
The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord. 2003; 3(2):81-92.
Score: 0.049
-
Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol. 2002 Dec; 97(12):2962-72.
Score: 0.048
-
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22; 369(8):699-710.
Score: 0.025
-
Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013 Aug 22; 369(8):711-21.
Score: 0.025
-
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013 Mar; 19(3):621-6.
Score: 0.025
-
Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013 Feb; 19(2):363-9.
Score: 0.024
-
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun; 60(6):780-7.
Score: 0.021
-
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009 Oct; 137(4):1250-60; quiz 1520.
Score: 0.019
-
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology. 2008 Mar; 134(3):688-95.
Score: 0.017
-
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007 Sep; 56(9):1232-9.
Score: 0.016
-
Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease. Inflamm Bowel Dis. 2004 Jul; 10 Suppl 2:S2-10.
Score: 0.013
-
Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol. 2002 Jul; 97(7):1748-54.
Score: 0.012
-
Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology. 1999 Jul; 117(1):58-64.
Score: 0.010